Protara Therapeutics receives fast track designation from U.S. FDA for intravenous choline chloride for the treatment of intestinal failure associated liver disease

Protara Therapeutics

26 May 2020 - Protara Therapeutics today announced that the U.S. FDA has granted fast track designation to intravenous choline chloride for the treatment of intestinal failure-associated liver disease. 

Intravenous choline chloride is the Company’s phase 3 ready investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition who have intestinal failure-associated liver disease.

Read Protara Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track